These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 20837760

  • 1. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
    Crandon JL, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5115-9. PubMed ID: 20837760
    [Abstract] [Full Text] [Related]

  • 2. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.
    Thabit AK, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):222-8. PubMed ID: 26482306
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [Abstract] [Full Text] [Related]

  • 6. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2928-33. PubMed ID: 19414568
    [Abstract] [Full Text] [Related]

  • 7. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
    Leonard SN, Supple ME, Gandhi RG, Patel MD.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [Abstract] [Full Text] [Related]

  • 9. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
    Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, Appelbaum PC.
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4217-24. PubMed ID: 19620338
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
    McMullen AR, Lainhart W, Wallace MA, Shupe A, Burnham CD.
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
    Xiong YQ, Abdelhady W, Tang C', Bayer AS.
    J Antimicrob Chemother; 2016 Oct; 71(10):2890-4. PubMed ID: 27353467
    [Abstract] [Full Text] [Related]

  • 15. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.
    Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP.
    Antimicrob Agents Chemother; 2012 May; 56(5):2342-6. PubMed ID: 22354302
    [Abstract] [Full Text] [Related]

  • 16. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ, Zhao M, Andes DR.
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
    [Abstract] [Full Text] [Related]

  • 17. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE, Fallon M, Moran JJ, Vanderloo JP.
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [Abstract] [Full Text] [Related]

  • 19. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models.
    Smith K, Gemmell CG, Lang S.
    Eur J Clin Microbiol Infect Dis; 2013 Oct; 32(10):1327-32. PubMed ID: 23624635
    [Abstract] [Full Text] [Related]

  • 20. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.